Sinovac Biotech, Ltd. (SVA) - NASDAQ
  • Fri, May 27, 6:20 AM
    • Sinovac Biotech (SVA) Q1 results: Revenues: $11M (+19.6%); R&D Expense: $2.1M (-4.5%); SG&A: $6.2M (-8.8%); Operating Loss: ($1.8M) (+10.0%); Net Loss: ($1.6M) (+38.5%); Loss Per Share: ($0.02) (+50.0%); Quick Assets: $62.5M (-2.0%); CF Ops: ($9.5M) (-15.9%).
    • No guidance given.
    | Fri, May 27, 6:20 AM
  • Thu, May 26, 6:02 PM
    • Sinovac Biotech (NASDAQ:SVA): Q1 EPS of -$0.02
    • Revenue of $10.95M (+19.0% Y/Y)
    • Press Release
    | Thu, May 26, 6:02 PM
  • Tue, Apr. 5, 7:05 AM
    • Sinovac Biotech (SVA) Q4 results: Revenues: $23M (+13.3%); R&D Expense: $2.9M (-17.1%); SG&A: $11.7M (+19.4%); Operating Income: $2.8M (+27.3%); Net Income: $1.3M (-45.8%); EPS: $0.01 (-66.7%); Non-GAAP EPS: $0.03 (unch).
    • FY2015 results: Revenues: $67.4M (+7.2%); R&D Expense: $9.5M (-12.8%); SG&A: $37.4M (+9.4%); Operating Income: $3.7M (+76.2%); Net Income: $0.5M (-58.3%); Loss Per Share: ($0.01) (-200.0%); Non-GAAP EPS: $0.03 (unch); Quick Assets: $63.8M (-30.1%).
    • No guidance given.
    | Tue, Apr. 5, 7:05 AM
  • Tue, Apr. 5, 6:24 AM
    • Sinovac Biotech (NASDAQ:SVA): Q4 EPS of $0.03
    • Revenue of $23M (+13.2% Y/Y) misses by $0.1M.
    • Press Release
    | Tue, Apr. 5, 6:24 AM
  • Nov. 11, 2015, 6:06 PM
    • Sinovac Biotech (NASDAQ:SVA): Q3 EPS of -$0.03
    • Revenue of $16.8M (-2.0% Y/Y)
    | Nov. 11, 2015, 6:06 PM
  • Aug. 12, 2015, 4:31 PM
    • Sinovac Biotech (NASDAQ:SVA): Q2 EPS of $0.04 beats by $0.05.
    • Revenue of $18.5M (+53.0% Y/Y) beats by $2.8M.
    | Aug. 12, 2015, 4:31 PM
  • May 15, 2015, 6:48 AM
    • Sinovac Biotech (SVA +1.6%) Q1 results: Revenues: $9.3M (-31.1%); COGS: $2.4M (-27.3%); R&D Expense: $2.2M (+29.4%); SG&A: $6.9M (-11.5%); Operating Loss: ($2.2M) (-466.7%); Net Loss: ($2.3M); Loss Per Share: ($0.04); Quick Assets: $63.1M (-31.0%); CF Ops: ($8.2M) (-41.4%).
    • No guidance given.
    | May 15, 2015, 6:48 AM
  • May 15, 2015, 12:23 AM
    • Sinovac Biotech (NASDAQ:SVA): Q1 EPS of -$0.04 misses by $0.05.
    • Revenue of $9.27M (-31.6% Y/Y) misses by $3.43M.
    | May 15, 2015, 12:23 AM
  • May 14, 2015, 5:30 PM
  • Apr. 20, 2015, 6:52 AM
    • Sinovac Biotech (SVA +0.8%) Q4 results: Revenues: $20.3M (-11.4%); COGS: $5.2M (-37.3%); R&D Expense: $3.5M (+40.0%); SG&A: $9.9M (+25.3%); Operating Income: $1.9M (-67.2%); Net Income: $1.3M (-77.6%); EPS: $0.02 (-80.0%); CF Ops: $7.5M (-62.3%).
    • FY2014 results: Revenues: $63.1M (-13.0%); COGS: $16.5M (-22.5%); R&D Expense: $11M (+31.0%); SG&A: $34.8M (+0.9%); Operating Income: $0.5M (-94.3%); Net Loss: ($0.9M) (-112.2%); Loss Per Share: ($0.02) (-115.4%); Quick Assets: $90M (-16.0%); CF Ops: ($8.6M) (-253.6%).
    • No guidance given.
    | Apr. 20, 2015, 6:52 AM
  • Apr. 20, 2015, 6:22 AM
    • Sinovac Biotech (NASDAQ:SVA): Q4 EPS of $0.02 beats by $0.01.
    • Revenue of $20.32M (-11.4% Y/Y) beats by $6.22M.
    • Shares +2.39% PM.
    | Apr. 20, 2015, 6:22 AM
  • Nov. 14, 2014, 4:55 PM
    • Sinovac Biotech (NASDAQ:SVA): Q3 EPS of $0 beats by $0.01.
    • Revenue of $17.1M (-22.6% Y/Y) misses by $3.45M.
    • Shares -2.8% AH.
    | Nov. 14, 2014, 4:55 PM
  • Aug. 14, 2014, 5:47 PM
    • Sinovac Biotech (NASDAQ:SVA): Q2 EPS of -$0.04 misses by $0.04.
    • Revenue of $12.1M (-30.9% Y/Y) misses by $5.1M.
    | Aug. 14, 2014, 5:47 PM
  • Aug. 14, 2014, 5:03 PM
    • Sinovac Biotech Ltd. (SVA -0.5%) Q2 results: Revenues: $12.1M (-30.9%); Operating Expenses: $12.0M (+5.1%); Operating Loss: ($3.0M) (-257.9%); Net Loss: ($2.6M) (-211.9%); Loss Per Share: ($0.04) (-300.0%); Quick Assets: $89.6M (-16.4%); Cash Burn: ($5.6M) (-70.3%).
    • No financial guidance given.
    | Aug. 14, 2014, 5:03 PM
  • Aug. 14, 2014, 1:05 PM
    • Sinovac Biotech (NASDAQ:SVA): Q2 EPS of -$0.04
    • Revenue of $12.1M (-30.7% Y/Y)
    | Aug. 14, 2014, 1:05 PM
Company Description
Sinovac Biotech Ltd. is biopharmaceutical company that focuses on research, development, manufacturing and commercialization of vaccines that protect against human infectious diseases including hepatitis A and B, seasonal influenza, H5N1 pandemic influenza and mumps, as well as animal rabies... More
Sector: Healthcare
Industry: Biotechnology
Country: China